Cargando…
Stromal NRG1 in luminal breast cancer defines pro-fibrotic and migratory cancer-associated fibroblasts
HER3 is highly expressed in luminal breast cancer subtypes. Its activation by NRG1 promotes activation of AKT and ERK1/2, contributing to tumour progression and therapy resistance. HER3-targeting agents that block this activation, are currently under phase 1/2 clinical studies, and although they hav...
Autores principales: | Berdiel-Acer, Mireia, Maia, Ana, Hristova, Zhivka, Borgoni, Simone, Vetter, Martina, Burmester, Sara, Becki, Corinna, Michels, Birgitta, Abnaof, Khalid, Binenbaum, Ilona, Bethmann, Daniel, Chatziioannou, Aristotelis, Hasmann, Max, Thomssen, Christoph, Espinet, Elisa, Wiemann, Stefan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8049869/ https://www.ncbi.nlm.nih.gov/pubmed/33692466 http://dx.doi.org/10.1038/s41388-021-01719-3 |
Ejemplares similares
-
Disentangling ERBB Signaling in Breast Cancer Subtypes—A Model-Based Analysis
por: Kemmer, Svenja, et al.
Publicado: (2022) -
IFNβ1 secreted by breast cancer cells undergoing chemotherapy reprograms stromal fibroblasts to support tumour growth after treatment
por: Maia, Ana, et al.
Publicado: (2021) -
Migratory and anti-fibrotic programmes define the regenerative potential of human cardiac progenitors
por: Poch, Christine M., et al.
Publicado: (2022) -
Effects of RET, NRG1 and NRG3 Polymorphisms in a Chinese Population with Hirschsprung Disease
por: Yang, Dehua, et al.
Publicado: (2017) -
Clonal heterogeneity in ER+ breast cancer reveals the proteasome and PKC as potential therapeutic targets
por: Beumers, Lukas, et al.
Publicado: (2023)